Tabula Rasa HealthCare (TRHC) Reaches New 52-Week High and Low at $41.90

Shares of Tabula Rasa HealthCare (NASDAQ:TRHC) hit a new 52-week high and low during trading on Tuesday . The stock traded as low as $41.90 and last traded at $41.35, with a volume of 240366 shares. The stock had previously closed at $40.57.

Several brokerages have commented on TRHC. Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a research note on Thursday, January 11th. William Blair reiterated an “outperform” rating on shares of Tabula Rasa HealthCare in a research note on Tuesday, March 13th. Citigroup began coverage on shares of Tabula Rasa HealthCare in a research note on Thursday, January 4th. They issued a “buy” rating on the stock. BidaskClub upgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. Finally, Oppenheimer began coverage on shares of Tabula Rasa HealthCare in a research note on Monday, December 18th. They issued an “outperform” rating and a $35.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $36.40.

How to Become a New Pot Stock Millionaire

The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.11 and a current ratio of 1.21. The stock has a market cap of $799.34, a PE ratio of -1,034.50, a PEG ratio of 8.88 and a beta of 2.34.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its earnings results on Monday, March 12th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.03). The business had revenue of $43.93 million for the quarter, compared to analysts’ expectations of $38.91 million. Tabula Rasa HealthCare had a net margin of 10.63% and a negative return on equity of 1.96%. The firm’s quarterly revenue was up 60.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 earnings per share. analysts forecast that Tabula Rasa HealthCare will post 0.18 EPS for the current year.

In other news, Director Bruce Luehrs sold 3,115 shares of the company’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $36.03, for a total transaction of $112,233.45. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $34.75, for a total transaction of $278,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 324,000 shares of company stock worth $11,309,958 over the last 90 days. Corporate insiders own 45.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in TRHC. Ranger Investment Management L.P. raised its position in shares of Tabula Rasa HealthCare by 896.7% during the 4th quarter. Ranger Investment Management L.P. now owns 777,341 shares of the company’s stock valued at $21,804,000 after buying an additional 699,352 shares in the last quarter. UBS Asset Management Americas Inc. purchased a new stake in shares of Tabula Rasa HealthCare during the 4th quarter valued at about $9,559,000. Peregrine Capital Management LLC purchased a new stake in shares of Tabula Rasa HealthCare during the 4th quarter valued at about $9,122,000. Castleark Management LLC purchased a new stake in shares of Tabula Rasa HealthCare during the 4th quarter valued at about $6,393,000. Finally, Allianz Asset Management GmbH purchased a new stake in shares of Tabula Rasa HealthCare during the 3rd quarter valued at about $3,801,000. Hedge funds and other institutional investors own 47.27% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Tabula Rasa HealthCare (TRHC) Reaches New 52-Week High and Low at $41.90” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/04/17/tabula-rasa-healthcare-trhc-reaches-new-52-week-high-and-low-at-41-90.html.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to enhance patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk.

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply